Search
Osanetant
go.drugbank.com/drugs/DB04872InvestigationalDeveloped by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System … This follows an earlier decision to discontinue development of eplivanserin for schizophrenia.
CX-046684
go.drugbank.com/drugs/DB19414ApprovedCX-046684 is a COVID-19 mRNA vaccine encoding the pre-fusion stabilized Spike glycoprotein (S) of the SARS-CoV-2 Omicron variant lineage KP.2. It is the active ingredient of the 2024-2025 formulation of Moderna's Spikevax vaccine.
Meplazumab
go.drugbank.com/drugs/DB16465InvestigationalMeplazumab is a humanized anti-CD147 antibody being investigated as an add-on therapy in patients with COVID-19 pneumonia.
Fenretinide
go.drugbank.com/drugs/DB05076InvestigationalIt is also effective as an antineoplastic agent.
Rhein
go.drugbank.com/drugs/DB13174ExperimentalRhein is an anthraquinone metabolite of rheinanthrone and senna glycoside is present in many medicinal plants including Rheum palmatum, Cassia tora, Polygonum multiflorum, and Aloe barbadensis [A19247]
Rilpivirine
go.drugbank.com/drugs/DB08864ApprovedInvestigational[A31331] Rilpivirine was developed by Tilbotec, Inc. and FDA approved on May 20, 2011. … [L31193] While previously administered once-monthly only, this combination product was granted FDA approval for dosing every two months on February 01, 2022 [L40084] and without the need for an oral lead-in
Metyrosine
go.drugbank.com/drugs/DB00765ApprovedInvestigationalAn inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines.
Pantethine
go.drugbank.com/drugs/DB11190ApprovedIt consists of two molecules of pantetheine that form a dimer via disufide linkages, and acts as an intermediate in the production of Coenzyme A. … Coenzyme A plays an essential role as a cofactor in the metabolism of lipids and carbohydrates including fatty acid oxidation, carbohydrate metabolism, pyruvate degradation, and amino acid catabolism [
Dalfampridine
go.drugbank.com/drugs/DB06637ApprovedInvestigationalDalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010.
Isometheptene
go.drugbank.com/drugs/DB06706ApprovedIsometheptene is a sympathomimetic drug that causes vasoconstriction. It is used for treating migraines and tension headaches.